• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Segment 2 - Genetics and Next-Generation Sequencing

Article

Dr Kumar continues his analysis of the genetic and familial probability of a patient being diagnosed with multiple myeloma.

Dr Kumar continues his analysis of the genetic and familial probability of a patient being diagnosed with multiple myeloma.

Dr Chernew questions the value of circulating plasma cells as independent prognostic markers in newly diagnosed multiple myeloma, as well as circulating serum microRNAs for diagnosis of multiple myeloma.

The panelists then discuss next-generation sequencing, deep sequencing, and ASO-qPCR in detecting minimal residual disease (MRD). Dr Kumar says there is a growing interest in MRD and explains all the emerging developments for detection of MRD.

Related Videos
Will Shapiro
Mila Felder, MD, FACEP
Kiana Mehring, MBA, director of strategic partnerships, managed care at Florida Cancer Specialists & Research Institute (FCS)
Miriam J. Atkins, MD, FACP, president of the Community Oncology Alliance (COA) and physician and partner of AO Multispecialty Clinic in Augusta, Georgia.
Dr Lucy Langer
Edward Arrowsmith, MD, MPH
Dr Kathi Mooney
Tiago Biachi de Castria, MD, PhD, Moffitt Cancer Center
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.